PolymarketVerifica disponibilitàSenza KYC2% di commissioneProbabilità implicita attualeSì 12%-0.0%
Qualita del mercato
52 / 100
Qualità mediaVolume 24h
238,8 €
Liquidità
2,4K €
Liquidità mediaBid / Ask
11.0% / 12.0%
Spread
9.1%
Spread ampioVariazione 7g
-4.5%
Dati di mercato
Aggiornato 5 minuti fa
12 gen 26, 23:0931 dic 26, 0:00
Trend
Esito scelto
Yes12%
Disponibile anche su Kalshi
Will the FDA approve retatrutide?
11.0%6m
-11.0%17%
-7.0%85%
-7.0%87%
+2 altri esiti
28 • Bassa qualitàSpread ampioBassa liquiditàMercato poco profondo
Volume totale102 €
Volume 24h5,1 €
KALSHIRegole
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
I dati di confronto sono solo informativi. I prezzi e la liquidità possono variare.
Mercati Correlati
Hantavirus pandemic in 2026?
145,3K €Sì: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
16,6K €Sì: 10%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
8,7K €Sì: 8%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
1,3K €0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
462,5 €Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETSAttivi in questi argomenti
Notizie Correlate
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsRegole
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs